Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Defining the role of immunotherapy in B-cell ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 382
Rating:

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Prof Franco Locatelli speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the role of immunotherapy in B-cell precursor acute lymphoblastic leukaemia (ALL).

He mentions a frontline, randomised trial which compares the addition of blinatumomab or two courses of consolidation therapy in high-risk patients, to examine whether immunotherapy can reduce toxicity and improve patient outcomes.

Prof Locatelli also describes future trials in this area, including one study that will further examine the role of blinatumomab and CART-T cells in relapsed/refractory patients.

In the future, Prof Locatelli believes that immunotherapy will be more commonly used instead of chemotherapy, due to its reduced toxicity.

 

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation